CM&R
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
 QUICK SEARCH:   [advanced]


     


First published online February 26, 2009
Clinical Medicine & Research
Volume 7, Number 3 : 93 -95
doi:10.3121/cmr.2008.828
© 2009 Marshfield Clinic
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
cmr.2008.828v1
7/3/93    most recent
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Calvo-Romero, J. M.
Right arrow Articles by Lima-Rodríguez, E. M.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Calvo-Romero, J. M.
Right arrow Articles by Lima-Rodríguez, E. M.

Original Research

Anticardiolipin Antibodies in Patients with Type 2 Diabetes Mellitus

José María Calvo-Romero, MD and Esther María Lima-Rodríguez, MD

José María Calvo-Romero, MD Internal Medicine Service Hospital Ciudad de Coria Coria (Cáceres) Spain
Esther María Lima-Rodríguez, MD Family Medicine Montehermoso (Cáceres) Spain

Corresponding Author: José María Calvo-Romero, MD, Internal Medicine Service, Hospital Ciudad de Coria, Cervantes 75, 10800 Coria (Cáceres), Spain, Email: jm.calvo{at}hotmail.es

Background: There is controversy about an increased prevalence of antiphospholipid antibodies in diabetic patients. The possible implications are little known.

Methods: We prospectively studied all consecutive outpatients with type 2 diabetes mellitus (DM) attended to in an Internal Medicine office. IgM and IgG anticardiolipin antibodies (ACA) were determined by standardized enzyme-linked immunoassay.

Results: Fifty-six patients were included. Only one patient (1.8%) had a titer of IgM ACA higher than 15 MPL units and no patient had a titer of IgG ACA higher than 15 GPL units. Six patients (10.7%) had low IgM ACA titers (4–15 MPL units) and 18 patients (32.1%) had low IgG ACA titers (4–15 GPL units). There were no differences in the frequencies of a low IgM or IgG ACA titer or in the means of IgM and IgG ACA titers in patients with complicated and uncomplicated DM, with and without cardiovascular disease, with and without nephropathy, or with and without retinopathy.

Conclusions: Moderate to high ACA titers must be exceptional in patients with type 2 DM. Low ACA titers may occur in patients with type 2 DM. These low titers do not seem to be associated with complicated DM, cardiovascular disease, nephropathy or retinopathy.


Key Words: Anticardiolipin • Antiphospholipid • Diabetes mellitus







HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Copyright © 2009 by Marshfield Clinic.